Leah Lawrence

Leah Lawrence

Articles by Leah Lawrence

Leah LawrenceHER2 Breast Cancer | March 28, 2025
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
Leah LawrenceHER2 Breast Cancer | March 28, 2025
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 10, 2024
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 3, 2024
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 2, 2024
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
Leah LawrenceASCO 2024: Focus on Lung Cancer | June 24, 2024
An analysis of the phase 3 trial evaluated multiple aspects of health-related quality of life.
Leah LawrenceASCO 2024: Focus on Lung Cancer | June 18, 2024
The study "confirmed the role of adagrasib compared to docetaxel" in terms of PFS, response rate, and intracranial response.
Leah LawrenceASCO 2024: Focus on Lung Cancer | June 10, 2024
The study findings "add critical evidence to support ongoing access to telehealth services" in these patients.
Leah LawrenceHemophilia | May 21, 2024
Patients with hemophilia A who received prophylaxis had a reduced risk for ICH.
Leah LawrenceHemophilia | May 14, 2024
Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.
Leah LawrenceHemophilia | May 14, 2024
Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.
Leah LawrenceHemophilia | May 10, 2024
Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.
Leah LawrenceLung Cancer | April 17, 2024
Just under a quarter of a million new cases of lung cancer were diagnosed in 2023, with 10-20% in non-smokers.
Leah LawrenceNon-Small Cell Lung Cancer | March 15, 2024
Although most of patients with NSCLC will receive immunotherapy, a growing percentage are eligible for targeted agents.
Leah LawrenceLung Cancer | February 23, 2024
Within the lung cancer realm, different types of AI are being applied to advance the understanding of the disease.
Leah LawrenceNon-Small Cell Lung Cancer | January 24, 2024
ESMO 2023 data reflected the fact that there are a growing number of patients with advanced NSCLC have genomic alterations.
Leah LawrenceLung Cancer | December 21, 2023
Climate change is directly relevant to lung cancer increases. This article explores the issue, and what can be done to help.